Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.

Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM.

Cancer Res. 2011 Mar 1;71(5):1893-903. doi: 10.1158/0008-5472.CAN-10-2458. Epub 2011 Jan 18.

2.

Therapeutic observations in MCF-7 aromatase xenografts.

Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):884s-8s. Review.

3.

Aromatase inhibitors and breast cancer.

Macedo LF, Sabnis G, Brodie A.

Ann N Y Acad Sci. 2009 Feb;1155:162-73. doi: 10.1111/j.1749-6632.2008.03689.x. Review.

PMID:
19250202
4.

Anti-tumor effects of letrozole.

Miller WR, Anderson TJ, Dixon JM.

Cancer Invest. 2002;20 Suppl 2:15-21. Review.

PMID:
12442345
5.

The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.

Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G.

Urol Oncol. 2009 Jan-Feb;27(1):53-63. doi: 10.1016/j.urolonc.2008.07.036. Review.

6.

Letrozole. A review of its use in postmenopausal women with advanced breast cancer.

Lamb HM, Adkins JC.

Drugs. 1998 Dec;56(6):1125-40. Review.

PMID:
9878997
7.

Entinostat for the treatment of breast cancer.

Trapani D, Esposito A, Criscitiello C, Mazzarella L, Locatelli M, Minchella I, Minucci S, Curigliano G.

Expert Opin Investig Drugs. 2017 Aug;26(8):965-971. doi: 10.1080/13543784.2017.1353077. Epub 2017 Jul 24. Review.

PMID:
28718331

Supplemental Content

Support Center